Autologous skin substitute for hard-to-heal ulcers: Retrospective analysis on safety, applicability, and efficacy in an outpatient and hospitalized setting

Autor: Blok, C.S., Vink, L., de Boer, E.M.J., van Montfrans, C., van den Hoogenband, H.M., Mooij, M.C., Gauw, S.A., Vloemans, J.A.F.P., Bruynzeel, I., Kraan, A., Kuik, J., Waaijman, T., Scheper, R.J., Gibbs, S.
Přispěvatelé: Oral Cell Biology, Orale Celbiologie (ORM, ACTA), MOVE Research Institute, CCA - Innovative therapy, Dermatology, Molecular cell biology and Immunology, Pathology
Jazyk: angličtina
Rok vydání: 2013
Předmět:
Zdroj: Wound Repair and Regeneration, 21(5), 667-676. Wiley-Blackwell
Blok, C S, Vink, L, de Boer, E M, van Montfrans, C, van den Hoogenband, H M, Mooij, M C, Gauw, S A, Vloemans, J A F P M, Bruynzeel, I, van Kraan, I, Kuik, J, Waaijman, T, Scheper, R J & Gibbs, S 2013, ' Autologous skin substitute for hard-to-heal ulcers: Retrospective analysis on safety, applicability, and efficacy in an outpatient and hospitalized setting ', Wound Repair and Regeneration, vol. 21, no. 5, pp. 667-676 . https://doi.org/10.1111/wrr.12082
Blok, C S, Vink, L, de Boer, E M J, van Montfrans, C, van den Hoogenband, H M, Mooij, M C, Gauw, S A, Vloemans, J A F P, Bruynzeel, I, Kraan, A, Kuik, J, Waaijman, T, Scheper, R J & Gibbs, S 2013, ' Autologous skin substitute for hard-to-heal ulcers: Retrospective analysis on safety, applicability, and efficacy in an outpatient and hospitalized setting ', Wound Repair and Regeneration, vol. 21, no. 5, pp. 667-676 . https://doi.org/10.1111/wrr.12082
ISSN: 1067-1927
DOI: 10.1111/wrr.12082
Popis: Chronic ulcers ((arterio)venous, decubitus, or postoperative) have no tendency to heal within a period of at least 3 months despite optimal therapy according to internationally accepted guidelines. This retrospective study evaluates the safety and efficacy of an autologous, dermal-epidermal skin substitute (SS) for treating ulcers of various origins. Ulcers were treated within 7 Dutch centers over 5 years. Sixty-six ulcers (size: 0.75-150 cm2; duration: 0.25-32 years) with a follow-up time of 24 weeks after a single-skin substitute application were assessed. Wound-bed preparation consisted of vacuum-assisted-closure-therapy (5 days, hospitalized) or application of acellular dermis (5-7 days, outpatient). Time to heal, adverse events, and recurrence 1 year after complete healing were recorded. Complete ulcer healing occurred in 36 of 66 ulcers (55%) at 24 weeks. At that time point, a further 29% of ulcers showed decrease in ulcer size between 50 and 99%. No difference was observed between the hospitalized vs. outpatient treatment with complete healing. There were 32 of 36 healed ulcers that were available for follow-up 1 year after complete closure, of which 27 (84%) were still closed. Only two minor/moderate possibly related adverse events were recorded. This retrospective analysis shows that SS provides a safe and successful treatment for particularly chronic ulcers of various origins.
Databáze: OpenAIRE
Externí odkaz: